This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.
Here's Why You Should Hold Baxter International (BAX) for Now
by Zacks Equity Research
Baxter (BAX) expects its bottom line to rise in the second quarter of 2019, courtesy to Renal Care and Clinical Nutrition businesses.
Baxter (BAX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Baxter (BAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
QDEL vs. BAX: Which Stock Is the Better Value Option?
by Zacks Equity Research
QDEL vs. BAX: Which Stock Is the Better Value Option?
Baxter's (BAX) New Sharesource 2.0 to Improve PD Treatment
by Zacks Equity Research
Baxter's (BAX) Sharesource 2.0 provides a more comprehensive patient treatment summary to enable faster clinical insights.
Baxter (BAX) Down 1.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Baxter (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Research Reports for Cigna, EOG Resources & Northrop Grumman
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Cigna (CI), EOG Resources (EOG) and Northrop Grumman (NOC).
BAX vs. CLPBY: Which Stock Is the Better Value Option?
by Zacks Equity Research
BAX vs. CLPBY: Which Stock Is the Better Value Option?
Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Higher revenues, growth in APAC and strong operating margin benefit Baxter's (BAX) Q1 earnings. However, weak performance at Medication Delivery and Clinical Nutrition remains a concern.
Baxter (BAX) Beats on Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Baxter International Inc. (BAX) reports solid Q1 performance on the back of higher revenues and strong operating margin.
Why the Earnings Surprise Streak Could Continue for Baxter (BAX)
by Zacks Equity Research
Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What Makes Baxter (BAX) a New Buy Stock
by Zacks Equity Research
Baxter (BAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Can Core Renal Care Unit Drive Baxter's (BAX) Q1 Earnings?
by Zacks Equity Research
Strong performance across Renal Care, Clinical Nutrition, Advanced Surgery and Acute Therapies businesses might aid Baxter (BAX) in Q1. However, lower sales at Pharmaceutical business might be a woe.
Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Invest in Baxter International Now
by Zacks Equity Research
Baxter (BAX) teams up with bioMerieux to treat acute kidney injury.
Baxter Showcases PN Product Portfolio at ASPEN Conference
by Zacks Equity Research
The launch of Clinolipid will be a crucial step toward Baxter's (BAX) goal of strengthening its lipid portfolio and offering enhanced health care to malnourished patients.
Moving Average Crossover Alert: Baxter International
by Zacks Equity Research
Baxter International Inc. (BAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Fresenius Medical's New Hemodialysis Software Gets FDA Nod
by Zacks Equity Research
Fresenius Medical (FMS) offers a wide range of HD and PD dialysis products.
Baxter (BAX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Moving Average Crossover Alert: Baxter International
by Zacks Equity Research
Baxter International Inc. (BAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Baxter (BAX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Baxter (BAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Baxter's (BAX) New Tie Up to Boost Acute Therapies Business
by Zacks Equity Research
Baxter's (BAX) Acute Therapies business is expected to grow 7-8% in 2019.
Top Analyst Reports for Home Depot, Oracle & Union Pacific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Home Depot (HD), Oracle (ORCL) and Union Pacific (UNP).
Baxter (BAX) Gets FDA Approval for Eptifibatide to Treat ACS
by Zacks Equity Research
Baxter's (BAX) Eptifibatide is a platelet aggregation inhibitor that prevents platelets-specialized blood cells clotting.
Baxter's Acute Therapies Profile Strong, Competition Rife
by Zacks Equity Research
Expanding product portfolio and strong presence in the international markets are key positives for Baxter (BAX) at the moment.
Baxter's (BAX) Earnings, Revenues Beat Estimates in Q4
by Zacks Equity Research
Baxter (BAX) gains from the Renal Care and Advanced Surgery units in fourth-quarter 2018; Clinical Nutrition revenues soft.